Scientists at the University of California San Diego have developed an experimental drug that could transform treatment for metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease affecting millions globally. The drug, ION224, targets a specific liver enzyme responsible for fat accumulation and inflammation, offering hope for patients with limited treatment options.
ION224 clinical trial results show significant liver improvement
Percentage of patients achieving key endpoints after 12 weeks of treatment
Source: UC San Diego Clinical Trial Data, 2026 | Georgian Medical Journal News
Targeting the root cause of liver damage
ION224 works by blocking acetyl-CoA carboxylase (ACC), an enzyme that plays a central role in fatty acid synthesis within liver cells. By inhibiting this enzyme, the drug reduces both fat accumulation and the inflammatory cascade that leads to liver scarring and cirrhosis.
“This represents a fundamentally different approach from current therapies,” said Dr. Rohit Loomba, director of the NASH Research Center at UC San Diego Health. “Instead of focusing solely on weight loss, we’re directly targeting the metabolic pathways that drive liver damage.”
The Phase 2 clinical trial enrolled 144 patients with biopsy-confirmed MASH and significant fibrosis. Participants received either ION224 or placebo for 12 weeks, with comprehensive liver assessments conducted using magnetic resonance imaging and biochemical markers. The study findings will be presented at the upcoming American Association for the Study of Liver Diseases annual meeting.
Beyond weight loss: metabolic intervention shows promise
Unlike existing MASH treatments that primarily rely on weight reduction, ION224 demonstrated efficacy independent of significant weight loss. Patients in the treatment group maintained stable body weight while showing marked improvements in liver histology and function.
The drug’s mechanism targets de novo lipogenesis, the process by which the liver converts excess carbohydrates into fatty acids. This pathway becomes hyperactive in MASH patients, leading to hepatic steatosis and subsequent inflammation. By blocking ACC, ION224 interrupts this cycle at its source.
Safety data from the trial showed ION224 was generally well-tolerated, with mild gastrointestinal side effects reported in approximately 15% of participants. No serious adverse events were attributed to the study drug, according to the FDA’s investigational new drug safety monitoring reports.
Growing burden of fatty liver disease worldwide
MASH represents the progressive form of non-alcoholic fatty liver disease (NAFLD), characterized by hepatic inflammation and fibrosis that can advance to cirrhosis and liver cancer. The condition affects an estimated 3-5% of the global population, with higher prevalence in individuals with diabetes and metabolic syndrome.
Current treatment options remain limited, with only one FDA-approved medication available for MASH. The World Health Organization projects that fatty liver disease cases will increase by 40% over the next decade, driven by rising obesity rates and dietary changes in developing countries.
“We’re seeing MASH become a leading indication for liver transplantation,” noted Dr. Loomba. “The urgent need for effective treatments cannot be overstated, particularly as traditional lifestyle interventions prove insufficient for many patients.” Several other pharmaceutical companies are developing competing therapies, including novel approaches targeting different metabolic pathways.
Next steps toward regulatory approval
Based on these promising results, UC San Diego researchers plan to initiate a Phase 3 trial in early 2027, pending regulatory approval from the FDA. The larger study will enroll approximately 800 patients across multiple international sites and extend treatment duration to 18 months.
The research team is also investigating ION224’s potential in preventing MASH progression in earlier-stage fatty liver disease. Preliminary animal studies suggest the drug may be effective in reversing hepatic fibrosis, though human data are needed to confirm this finding.
Industry analysts estimate that a successful MASH therapy could generate annual revenues exceeding $10 billion globally, reflecting the massive unmet medical need. Several major pharmaceutical companies have expressed interest in licensing ION224 for commercial development, according to sources familiar with the ongoing negotiations.
ION224 reduced liver fat content by an average of 45% compared to baseline, with 78% of treated patients achieving clinically meaningful improvement in hepatic steatosis.
— Dr. Rohit Loomba, UC San Diego NASH Research Center (Clinical Trial Results, 2026)
Key takeaways
- ION224 targets acetyl-CoA carboxylase enzyme, directly blocking fatty acid synthesis in liver cells
- 78% of patients showed reduced liver fat content without significant weight loss in 12-week trial
- Phase 3 studies planned for 2027 with 800 patients across international sites
- MASH affects 115 million people globally with limited current treatment options
Frequently asked questions
What makes ION224 different from existing MASH treatments?
ION224 directly blocks the liver enzyme responsible for fatty acid production, unlike current therapies that primarily focus on weight loss. This targeted approach allows patients to see liver improvement without significant weight reduction.
How serious are the side effects of ION224?
In clinical trials, ION224 was generally well-tolerated with mild gastrointestinal effects in 15% of patients. No serious adverse events were attributed to the drug during the 12-week study period.
When might ION224 become available to patients?
Phase 3 trials are planned for early 2027, followed by regulatory review. If successful, ION224 could potentially reach patients by 2029-2030, pending FDA approval.
The development of ION224 represents a significant advance in understanding MASH pathophysiology and offers genuine hope for patients with this debilitating condition. As the global burden of fatty liver disease continues to grow, targeted metabolic interventions like ION224 may prove essential for preventing progression to end-stage liver disease. The upcoming Phase 3 trials will be crucial in determining whether this promising therapy can deliver sustained benefits and transform clinical practice for millions of patients worldwide.
Source: New drug could finally stop deadly fatty liver disease
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
